Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Resistance of hypoxic tumor cells to radiation is a significant reason of failure in the
local control of tumors, especially the squamous cell carcinomas. Preclinical models have
shown that Endostar may transiently "normalize" the tumor vasculature to make it more
efficient for oxygen delivery, thereby providing a window of opportunity for enhanced
sensitivity to radiation treatment. This study is to evaluate the safety, toxicity, and
efficacy of the addition of Endostar Continued Pumping into Vein to the standard CCRT regimen
in patients with unresectable stage III NSCLC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Collaborators:
Beijing Cancer Hospital Chinese Academy of Medical Sciences Fudan University Fujian Cancer Hospital Jiangsu Cancer Institute & Hospital Shandong Cancer Hospital and Institute The First People's Hospital of Lianyungang Tianjin Medical University Cancer Institute and Hospital